In addition, Farmaki et al. reported that using ONC201/TIC10 in combination with everolimus inhibited the growth of drug-resistant cells, thereby providing an effective add-on therapeutic strategy for everolimus-resistant patients with metastatic estrogen receptor-positive (ER+) breast cancer [47]. Here, ESR1 is linked to breast carcinoma.